Tag: sun pharma
quarterly results: Q4 results this week: ITC, ONGC, Sun Pharma, Nykaa, Ircon International and IRFC
Various widely tracked companies like ITC, ONGC, IRFC, Ircon International, BHEL, BEL, Sun Pharma, Nykaa, Tata Investment Corporation, Hindalco, Ashok Leyland, and Divi’s lab will [Read more about this post…]
Cipla, Aurobindo, Torrent are 3 preferred picks of HSBC on healthy Q4 expectations
The strong growth in the US markets led by large product launches has helped drive earnings growth leading to gains for Sun Pharma, Lupin ,Dr [Read more about this post…]
Ahead of Market: 10 things that will decide D-Street action on Monday
Domestic benchmark equity indices dropped 1% each on Friday, dragged by financial and IT stocks, as hot US inflation data dimmed hopes of early interest [Read more about this post…]
Market Trading Guide: Godrej Properties, Granules among 5 stock recommendations for Monday – Gainers Galore
Target Price: Rs 1100 Stop Loss: Rs 1020 On the daily chart, Great Eastern Shipping Company Ltd has broken out of a Rectangle Pattern, signaling [Read more about this post…]
stock market outlook: Ahead of Market: 10 things that will decide stock action on Monday
Indian shares logged third straight weekly gains on Friday, led by financials, while the ce ntral bank kept a key policy rate unchanged, as expected. [Read more about this post…]
Stocks in news: Stocks in news: PB Fintech, Maruti, L&T, Sun Pharma, TCS
Equity indices failed to capitalize on Monday’s gain and shed nearly 1% on Tuesday due to sharp selloff in select heavyweights in the final hour. [Read more about this post…]
Q3 results this week: ITC, Adani Ports, Bajaj Finance, IndiGo, SBI, Tata Motors and others
Various widely tracked companies like ITC, Bajaj Finance, NTPC, L&T, Bajaj Finserv, Sun Pharma, Maruti Suzuki, Titan, Adani Enterprises, Adani Ports, Tata Motors, SBI, and [Read more about this post…]
Stocks to Watch: Sun Pharma, Apollo Tyres, Biocon, Vedanta
Sun Pharma: The company has agreed to acquire a 16.7% stake in Massachusetts-based Lyndra Therapeutics for $30 million. Lyndra develops novel delivery technology for long-acting [Read more about this post…]
